Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Gets Downgrade from Wall Street Zen

Key Points

• Wall Street Zen downgraded Jazz Pharmaceuticals from “buy” to “hold,” although analyst sentiment overall remains positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $293.45.
• Jazz beat quarterly estimates, posting $1.24 billion in revenue versus $1.21 billion expected, with revenue up 10.4% year over year. The article also cites reports that the company raised its 2026 revenue outlook to about $4.78 billion–$4.85 billion.
• Shares opened at $234.76 and were reported up 3.3%; company insiders have sold 102,534 shares worth about $25.2 million over the last quarter.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

JAZZ has been the subject of several other research reports. Piper Sandler boosted their target price on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a "buy" rating in a research report on Wednesday, October 7th. Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a "buy" rating in a research report on Wednesday, August 26th. Finally, Royal Bank Of Canada lifted their price target on Jazz Pharmaceuticals from $296.00 to $305.00 and gave the company an "outperform" rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $293.45.

Jazz Pharmaceuticals Stock Up 3.3%

Shares of JAZZ stock opened at $234.76 on Friday. Jazz Pharmaceuticals has a 52 week low of $128.80 and a 52 week high of $266.38. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The company's fifty day simple moving average is $229.39 and its two-hundred day simple moving average is $217.74. The stock has a market cap of $15.24 billion, a P/E ratio of 19.01, a PEG ratio of 0.43 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating analysts' consensus estimates of ($4.03) by $0.15. The firm had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.55% and a net margin of 4.37%. The firm's quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm posted $8.13 earnings per share. Analysts predict that Jazz Pharmaceuticals will post 10.88 EPS for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Renee D. Gala sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $243.03, for a total value of $486,060.00. Following the transaction, the chief executive officer owned 143,394 shares in the company, valued at $34,849,043.82. This trade represents a 1.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Patricia Carr sold 1,413 shares of the firm's stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $231.36, for a total transaction of $326,911.68. Following the sale, the chief accounting officer owned 6,512 shares of the company's stock, valued at $1,506,616.32. The trade was a 17.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 102,534 shares of company stock worth $25,185,243. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. USA Financial Formulas purchased a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $25,000. Pension & Wealth Management Advisors Inc. acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth $32,000. Ameritas Advisory Services LLC bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $47,000. Westpac Banking Corp bought a new stake in shares of Jazz Pharmaceuticals in the first quarter worth about $51,000. Finally, Elevation Wealth Partners LLC grew its holdings in Jazz Pharmaceuticals by 156.4% during the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company's stock worth $60,000 after purchasing an additional 158 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.